<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176032</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100AES02</org_study_id>
    <secondary_id>2009-016735-36</secondary_id>
    <nct_id>NCT01176032</nct_id>
  </id_info>
  <brief_title>ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling</brief_title>
  <acronym>ALLMARK</acronym>
  <official_title>The &quot;ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK)&quot; Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy of aliskiren for reducing circulating levels
      of biomarkers of left ventricular (LV) remodeling associated with LV hypertrophy (LVH) in
      hypertensive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood pressure was measured 10 weeks after starting treatment (visit 3). All patients who did
      not achieve the required blood pressure (&lt;140/90 mmHg) after 8 weeks of treatment at the
      maximum doses of study medication were given 5 mg of amlodipine in addition to the study
      medication in order to reach the required BP (&lt;140/90 mmHg).

      The patient's blood pressure was assessed at visit 4 (week 18) and if it was still not at the
      required level (&lt;140/90 mmHg), the dose of amlodipine was increased to 10 mg.

      Blood pressure was again assessed at visit 5 (week 26) and if the required values had not
      been reached (&lt;140/90 mmHg), a 12.5 mg dose of hydrochlorothiazide (HCTZ) was prescribed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>PICP is a measure of blood concentration of procollagen I carboxy-terminal propeptide (PICP), a peptide released from the myocardium when procollagen is converted to type I collagen. This biomarker exhibits good specificity and sensitivity for identifying myocardial fibrosis in hypertension.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarkers in Heart Disease</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>The plasma level of biomarker parameter (aldosterone (Aldo)) used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>The plasma level of biomarker parameter plasma aldosterone used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline, Week 10,18,26,36</time_frame>
    <description>The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline, Week 10,18,26,36</time_frame>
    <description>The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate</measure>
    <time_frame>Baseline, Week10,18,26,36</time_frame>
    <description>Response rate was defined as the proportion of patients with a satisfactory systolic BP response (SBP &lt; 140 mmHg or reduction of ≥ 10 mmHg compared to baseline) and a satisfactory diastolic BP response (DBP &lt; 90 mmHg or reduction of ≥ 5 mmHg compared to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP &lt; 140 mmHg and DBP &lt; 90 mmHg Compared to Baseline</measure>
    <time_frame>Week10,18,26,36</time_frame>
    <description>The control rate was defined as the proportion of patients with SBP &lt; 140 mmHg and DBP &lt; 90 mmHg compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs</measure>
    <time_frame>Baseline, Week 10,18,26</time_frame>
    <description>The rate of use of first and second antihypertensive rescue drugs added was also assessed at all visits after week 2. The rescue drug at week 10 and 18 for those patients not achieving the required BP was amlodipine, Patients who did not achieve the required BP at week 26 were treated with hydrochlorothiazide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hypertension</condition>
  <condition>Left Ventricle Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (&lt;140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.
HCTZ 12.5mg was prescribed at week 26 if the required values (&lt;140/90 mmHg) had not been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lostaran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (&lt;140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.
HCTZ 12.5mg was prescribed at week 26 if the required values (&lt;140/90 mmHg) had not been reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 300 mg film coated tablets</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 100 mg tablets</description>
    <arm_group_label>Lostaran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5mg was given to patients who did not achieve the required blood pressure (&lt;140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_label>Lostaran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide (HCTZ)</intervention_name>
    <description>HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (&lt;140/90 mmHg) had not been reached.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_label>Lostaran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with hypertension

          -  Confirmed concentric left ventricular hypertrophy:

          -  LVMI &gt; 49.2 g/m2.7 for men and &gt;46.7 g/m2.7 for women

          -  Relative wall thickness &gt; 0.42

        Exclusion Criteria:

          -  Sever or secondary HTN

          -  LV ejection fraction of &lt;40%

          -  Patient with compelling indication to ACEIs or ARBs or BB

          -  History of myocardial infarction, coronary artery bypass surgery, PTC intervention,
             TIA or stroke within 6 months of study entry

          -  History of collagenopathies, osteopathy

          -  eGFR &lt;30 ml/min/1,73 m2, serum potassium ≥5,2 mEq/L

          -  Morbid obesity (BMI ≥ 42 kg/m2

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sanlúcar de Barrameda</city>
        <state>Andalucia</state>
        <zip>11540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrera</city>
        <state>Andalucia</state>
        <zip>41710</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burgos</city>
        <state>Castilla y Leon</state>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Girona</city>
        <state>Cataluña</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrevieja (Alicante)</city>
        <state>Comunidad Valenciana</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galdakano</city>
        <state>Pais Vasco</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>País Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vitoria</city>
        <state>País Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <results_first_submitted>April 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2014</results_first_posted>
  <last_update_submitted>July 22, 2014</last_update_submitted>
  <last_update_submitted_qc>July 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aliskiren</keyword>
  <keyword>hypertension</keyword>
  <keyword>concentric LVH</keyword>
  <keyword>LV remodeling</keyword>
  <keyword>LVMI</keyword>
  <keyword>biomarkers</keyword>
  <keyword>PICP</keyword>
  <keyword>CT-1</keyword>
  <keyword>MMP-1</keyword>
  <keyword>TIMP-1</keyword>
  <keyword>AnxA5</keyword>
  <keyword>Aldosterone</keyword>
  <keyword>Essential hypertension with concentric left ventricle hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
        </group>
        <group group_id="P2">
          <title>Lostaran</title>
          <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37">&quot;Started&quot; indicates randomized and safety population</participants>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Informed consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not available</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) population</population>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
        </group>
        <group group_id="B2">
          <title>Lostaran</title>
          <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.34" spread="9.34"/>
                    <measurement group_id="B2" value="58.05" spread="10.34"/>
                    <measurement group_id="B3" value="59.12" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)</title>
        <description>PICP is a measure of blood concentration of procollagen I carboxy-terminal propeptide (PICP), a peptide released from the myocardium when procollagen is converted to type I collagen. This biomarker exhibits good specificity and sensitivity for identifying myocardial fibrosis in hypertension.</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)</title>
          <description>PICP is a measure of blood concentration of procollagen I carboxy-terminal propeptide (PICP), a peptide released from the myocardium when procollagen is converted to type I collagen. This biomarker exhibits good specificity and sensitivity for identifying myocardial fibrosis in hypertension.</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment.</population>
          <units>ug/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.22" spread="20.37"/>
                    <measurement group_id="O2" value="-4.25" spread="24.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biomarkers in Heart Disease</title>
        <description>The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biomarkers in Heart Disease</title>
          <description>The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cardiotrophin-1 (CT-1) (n=32,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169.15" spread="561.51"/>
                    <measurement group_id="O2" value="-128.23" spread="568.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>matrix metalloproteinase-1 (MMP-1) (n=32,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="13.33"/>
                    <measurement group_id="O2" value="5.51" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tissue inhibitor of MMPs (TIMP-1) (n=32,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="59.18"/>
                    <measurement group_id="O2" value="9.15" spread="42.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>annexin A5 (AnxA5) (n=31,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="7.33"/>
                    <measurement group_id="O2" value="-1.21" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP (n=31,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.66" spread="165.21"/>
                    <measurement group_id="O2" value="-7.55" spread="38.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease</title>
        <description>The plasma level of biomarker parameter (aldosterone (Aldo)) used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease</title>
          <description>The plasma level of biomarker parameter (aldosterone (Aldo)) used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="27.78"/>
                    <measurement group_id="O2" value="-7.90" spread="76.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV end-diastolic volume (n=22,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="35.65"/>
                    <measurement group_id="O2" value="0.54" spread="33.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV end-systolic volume (n=22,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="12.24"/>
                    <measurement group_id="O2" value="0.64" spread="21.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV ejection fraction Teicholz(n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.11"/>
                    <measurement group_id="O2" value="0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV ejection fraction Simpson(n=22,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.14"/>
                    <measurement group_id="O2" value="0.00" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>mm/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.17"/>
                    <measurement group_id="O2" value="-0.22" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>cm3/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="17.94"/>
                    <measurement group_id="O2" value="-2.27" spread="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)</title>
        <description>Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)</title>
          <description>Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.05" spread="18.98"/>
                    <measurement group_id="O2" value="-7.96" spread="18.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.</title>
        <description>The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.</title>
          <description>The plasma level of biomarkers parameters used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI). The following biomarkers were analyzed: cardiotrophin-1 (CT-1), matrix metalloproteinase-1 (MMP-1); tissue inhibitor of MMPs (TIMP-1); annexin A5 (AnxA5); N-terminal prohormone of B-type natriuretic peptide (NT-proBNP)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CT-1(n=15,17,16,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-289.18" spread="608.91"/>
                    <measurement group_id="O2" value="-63.23" spread="510.91"/>
                    <measurement group_id="O3" value="156.89" spread="599.29"/>
                    <measurement group_id="O4" value="-345.47" spread="443.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANXA5 (n=15,16,16,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="3.70"/>
                    <measurement group_id="O2" value="-0.74" spread="9.73"/>
                    <measurement group_id="O3" value="-1.73" spread="4.21"/>
                    <measurement group_id="O4" value="-0.81" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-1(n=15,17,16,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="10.28"/>
                    <measurement group_id="O2" value="4.99" spread="15.80"/>
                    <measurement group_id="O3" value="5.47" spread="7.88"/>
                    <measurement group_id="O4" value="5.54" spread="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMP-1 (n=15,17,16,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.01" spread="73.00"/>
                    <measurement group_id="O2" value="7.51" spread="44.38"/>
                    <measurement group_id="O3" value="21.38" spread="38.40"/>
                    <measurement group_id="O4" value="-0.16" spread="44.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP (n=15,16,15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.00" spread="214.06"/>
                    <measurement group_id="O2" value="16.46" spread="108.69"/>
                    <measurement group_id="O3" value="-3.68" spread="23.78"/>
                    <measurement group_id="O4" value="-10.60" spread="46.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine</title>
        <description>The plasma level of biomarker parameter plasma aldosterone used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI).</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine</title>
          <description>The plasma level of biomarker parameter plasma aldosterone used to measure improvement in left ventricular (LV) function or reduction in left ventricular mass index (LVMI).</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="21.36"/>
                    <measurement group_id="O2" value="-5.89" spread="32.54"/>
                    <measurement group_id="O3" value="-3.12" spread="32.45"/>
                    <measurement group_id="O4" value="-11.55" spread="98.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipinet</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV end-diastolic volume by Simpson's rule, and LV end-systolic volume by Simpson's rule</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV end-diastolic volume (n=11,11,15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="40.43"/>
                    <measurement group_id="O2" value="-2.00" spread="31.51"/>
                    <measurement group_id="O3" value="5.01" spread="38.15"/>
                    <measurement group_id="O4" value="-2.98" spread="29.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV end-systolic volume (n=11,11, 15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.93" spread="13.24"/>
                    <measurement group_id="O2" value="1.09" spread="11.44"/>
                    <measurement group_id="O3" value="6.11" spread="23.82"/>
                    <measurement group_id="O4" value="-3.69" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipinet</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LV ejection fraction (Teicholz), and LV ejection fraction (Simpson)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV ejection fraction Teicholz (n=14,15,16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.09"/>
                    <measurement group_id="O2" value="-0.00" spread="0.13"/>
                    <measurement group_id="O3" value="-0.00" spread="0.07"/>
                    <measurement group_id="O4" value="0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV ejection fraction Simpson(n=11,11,15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.10"/>
                    <measurement group_id="O2" value="-0.01" spread="0.17"/>
                    <measurement group_id="O3" value="-0.02" spread="0.12"/>
                    <measurement group_id="O4" value="0.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipinet</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: LA diameter</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>mm/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="1.12"/>
                    <measurement group_id="O2" value="-0.07" spread="1.27"/>
                    <measurement group_id="O3" value="-0.19" spread="0.96"/>
                    <measurement group_id="O4" value="-0.24" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine</title>
        <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipinet</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine</title>
          <description>Reductions in the following measurements were analysed between the baseline visit and the final visit: left atrial volume (biplane Simpson's method)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment. Patients with both baseline and week 36 assessment were included in this analysis.</population>
          <units>cm3/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.88" spread="15.74"/>
                    <measurement group_id="O2" value="7.78" spread="17.14"/>
                    <measurement group_id="O3" value="-7.42" spread="24.37"/>
                    <measurement group_id="O4" value="1.30" spread="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine</title>
        <description>Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren + Amlodipinet</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
          <group group_id="O3">
            <title>Losartan</title>
            <description>losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan + Amlodipine</title>
            <description>5 mg of amlodipine in addition to the study medication in order to reach the required BP (&lt;140/90 mmHg). At week 18 the dose of amlodipine can be increased to 10mg if the required level (&lt;140/90 mmHg) was still not achieved.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine</title>
          <description>Echocardiogram was performed at week 1 and at week 36. Reduction in LVMI is defined as the difference between the LVMI at the final visit and the baseline LVMI</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>g/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.68" spread="18.95"/>
                    <measurement group_id="O2" value="-10.26" spread="19.40"/>
                    <measurement group_id="O3" value="-3.59" spread="13.46"/>
                    <measurement group_id="O4" value="-11.46" spread="21.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)</title>
        <description>The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values</description>
        <time_frame>Baseline, Week 10,18,26,36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)</title>
          <description>The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Week 10 (n=30,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="12.89"/>
                    <measurement group_id="O2" value="-4.03" spread="16.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 18 (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.77" spread="12.25"/>
                    <measurement group_id="O2" value="-8.44" spread="17.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 26 (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.69" spread="15.05"/>
                    <measurement group_id="O2" value="-10.40" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 36 (n=32,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.87" spread="19.26"/>
                    <measurement group_id="O2" value="-8.88" spread="15.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)</title>
        <description>The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values</description>
        <time_frame>Baseline, Week 10,18,26,36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)</title>
          <description>The mean systolic BP (SBP) and diastolic BP (DBP) readings for the aliskiren and losartan treatment groups, the difference in these values between the two groups and the comparison of post-baseline vs. baseline values</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Week 10 (n=30,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="10.22"/>
                    <measurement group_id="O2" value="-3.15" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 18 (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.34" spread="10.66"/>
                    <measurement group_id="O2" value="-7.07" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 26 (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.34" spread="11.37"/>
                    <measurement group_id="O2" value="-6.94" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 36 (n=32,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.19" spread="10.32"/>
                    <measurement group_id="O2" value="-6.68" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate</title>
        <description>Response rate was defined as the proportion of patients with a satisfactory systolic BP response (SBP &lt; 140 mmHg or reduction of ≥ 10 mmHg compared to baseline) and a satisfactory diastolic BP response (DBP &lt; 90 mmHg or reduction of ≥ 5 mmHg compared to baseline)</description>
        <time_frame>Baseline, Week10,18,26,36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate</title>
          <description>Response rate was defined as the proportion of patients with a satisfactory systolic BP response (SBP &lt; 140 mmHg or reduction of ≥ 10 mmHg compared to baseline) and a satisfactory diastolic BP response (DBP &lt; 90 mmHg or reduction of ≥ 5 mmHg compared to baseline)</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP &lt; 140 mmHg and DBP &lt; 90 mmHg Compared to Baseline</title>
        <description>The control rate was defined as the proportion of patients with SBP &lt; 140 mmHg and DBP &lt; 90 mmHg compared to baseline</description>
        <time_frame>Week10,18,26,36</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP &lt; 140 mmHg and DBP &lt; 90 mmHg Compared to Baseline</title>
          <description>The control rate was defined as the proportion of patients with SBP &lt; 140 mmHg and DBP &lt; 90 mmHg compared to baseline</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control rate at Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control rate at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control rate at Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control rate at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs</title>
        <description>The rate of use of first and second antihypertensive rescue drugs added was also assessed at all visits after week 2. The rescue drug at week 10 and 18 for those patients not achieving the required BP was amlodipine, Patients who did not achieve the required BP at week 26 were treated with hydrochlorothiazide</description>
        <time_frame>Baseline, Week 10,18,26</time_frame>
        <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lostaran</title>
            <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs</title>
          <description>The rate of use of first and second antihypertensive rescue drugs added was also assessed at all visits after week 2. The rescue drug at week 10 and 18 for those patients not achieving the required BP was amlodipine, Patients who did not achieve the required BP at week 26 were treated with hydrochlorothiazide</description>
          <population>Intention-to-treat (ITT) population included all patients included in the safety population who had a baseline assessment of the primary variable and at least one post-baseline assessment</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Week 10 (amlodipine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 18 (amlodipine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Week 26 (hydrochlorothiazide)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks</description>
        </group>
        <group group_id="E2">
          <title>Losartan</title>
          <description>Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

